Laxar, D.;                     Schaden, E.;                     Wiegele, M.;                     Hötzenecker, K.;                     Schwarz, S.;                     Gratz, J.    
        Use of Recombinant Activated Factor VII in Bleeding Lung Transplant Patients Undergoing Perioperative ECMO Therapy. J. Clin. Med. 2023, 12, 3020.
    https://doi.org/10.3390/jcm12083020
    AMA Style
    
                                Laxar D,                                 Schaden E,                                 Wiegele M,                                 Hötzenecker K,                                 Schwarz S,                                 Gratz J.        
                Use of Recombinant Activated Factor VII in Bleeding Lung Transplant Patients Undergoing Perioperative ECMO Therapy. Journal of Clinical Medicine. 2023; 12(8):3020.
        https://doi.org/10.3390/jcm12083020
    
    Chicago/Turabian Style
    
                                Laxar, Daniel,                                 Eva Schaden,                                 Marion Wiegele,                                 Konrad Hötzenecker,                                 Stefan Schwarz,                                 and Johannes Gratz.        
                2023. "Use of Recombinant Activated Factor VII in Bleeding Lung Transplant Patients Undergoing Perioperative ECMO Therapy" Journal of Clinical Medicine 12, no. 8: 3020.
        https://doi.org/10.3390/jcm12083020
    
    APA Style
    
                                Laxar, D.,                                 Schaden, E.,                                 Wiegele, M.,                                 Hötzenecker, K.,                                 Schwarz, S.,                                 & Gratz, J.        
        
        (2023). Use of Recombinant Activated Factor VII in Bleeding Lung Transplant Patients Undergoing Perioperative ECMO Therapy. Journal of Clinical Medicine, 12(8), 3020.
        https://doi.org/10.3390/jcm12083020